

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **GENERTEC UNIVERSAL MEDICAL GROUP COMPANY LIMITED**

**通用環球醫療集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code : 2666)**

### **UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE FIRST QUARTER OF 2022**

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group Company Limited (the “**Company**”), together with its subsidiaries (the “**Group**”), for the first quarter ended 31 March 2022.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first quarter of 2022, under the frequent outbreaks and continuing impact of the pandemic in China, the Group adhered to strategic planning and made great efforts to promote business development. Member medical institutions of the Group ensured daily operations and adhered to their own discipline, operation and service capacity building while undertaking important local pandemic prevention responsibilities. For the three months ended 31 March 2022, the Group achieved a stable growth in operating results: the revenue of the Group increased by approximately 15%, the profit for the period increased by approximately 8%, and the profit for the period attributable to ordinary shareholders of the parent increased by approximately 9% as compared with the corresponding period of 2021. Among others:

In respect of finance business, the Group continued to advance steadily and developed business in an orderly manner under the premise of fully ensuring risk control and asset safety. At 31 March 2022, as compared with the end of 2021, interest-earning assets of the Group achieved a sustainable growth, while net interest margin and net interest spread both remained stable and assets quality remained in a good condition.

In respect of hospital group operation, the nucleic acid tests conducted by the member medical institutions managed by the Group in the first quarter significantly increased due to the impact of the pandemic in many places, resulting in a significant increase in the total number of visits, which increased by approximately 10%, with the impact of nucleic acid visits being excluded, as compared with the corresponding period of 2021. The inpatients visits increased by only 3% as a result of the impact of the pandemic, the medical examinations visits increased by approximately 25%, and the total medical business income increased by approximately 8% as compared with the corresponding period of 2021. The overall operation of the hospital group was most affected by the pandemic in Shaanxi in this January, and gradually recovered in February and March. It is expected that in the early second quarter of this year, the pandemic in many places across the country would have certain impact on the operation of the hospital group.

In respect of financing support, the Group actively took advantage of onshore and offshore financing instruments while ensuring its reasonable and sufficient capital liquidity and prudent debt maturity structure. The average funding cost for the first quarter of this year remained stable as compared to that of 2021.

In addition, references are made to the announcements of the Company dated 4 June 2019, 5 March 2020, 19 May 2020, 8 April 2021, 16 September 2021 and 20 December 2021 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB3.36 billion in the inter-bank market in the People's Republic of China (the “**PRC**”) by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) (“**CULC**”), a wholly-owned subsidiary of the Company. In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of CULC for the three months ended 31 March 2022 (the “**CULC Consolidated Financial Information**”) has been published on the websites of Shanghai Clearing House ([www.shclearing.com](http://www.shclearing.com)) and China Foreign Exchange Trade System ([www.chinamoney.com.cn](http://www.chinamoney.com.cn)) on 27 April 2022. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of CULC:

## PRINCIPAL CONSOLIDATED FINANCIAL DATA OF CULC

	<i>Unit: Thousand Yuan</i> <i>Currency: RMB</i>	
	<b>As at 31 March 2022</b> <b>(unaudited)</b>	<b>As at 31 December 2021</b> <b>(audited)</b>
Total assets	77,037,281	69,647,946
Total equity	18,642,911	18,217,394
	<b>For the three months ended</b> <b>31 March 2022</b> <b>(unaudited)</b>	<b>For the three months ended</b> <b>31 March 2021</b> <b>(unaudited)</b>
Operating income	2,664,252	2,317,444
Profit for the period	527,750	482,498

Net cash flows from operating  
activities

755,654

4,529

The Company hereby reminds investors that the above unaudited operation summary for the first quarter ended 31 March 2022 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The CULC Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of CULC, which does not provide a full picture of the operation status of the Group or comparison with the Group.

**Investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Genertec Universal Medical Group Company  
Limited**  
通用環球醫療集團有限公司  
**Peng Jiahong**  
*Chairwoman of the Board*

Beijing, PRC, 27 April 2022

*As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Chairwoman), Mr. Wang Wenbing and Mr. Yu Gang; the non-executive directors of the Company are Mr. Zhao Yan (Vice-chairman), Mr. Tong Chaoyin, Mr. Che Lingyun and Mr. Zhu Ziyang; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Han Demin and Mr. Liao Xinbo.*